David Grainger, Centessa chief innovation officer (Medicxi)
Centessa provides peek at rare disease drug from extremely tiny study, leaving several questions unanswered
The race to develop drugs for the rare genetic disease alpha-1 antitrypsin deficiency is marching on after Vertex’s flop earlier this year, and Centessa Pharmaceuticals …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
